Cargando…
A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer
A 69-year-old female visited our department with a diagnosis of rectosigmoid cancer and multiple hepatic metastases (stage IV). Abdominal CT revealed multiple metastatic lesions in the bilateral lobes of the liver. The primary lesion was considered to be resectable, and high anterior resection of th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037991/ https://www.ncbi.nlm.nih.gov/pubmed/21326855 http://dx.doi.org/10.1159/000323138 |
_version_ | 1782198048156286976 |
---|---|
author | Kawasaki, Atsushi Mimatsu, Kenji Oida, Takatsugu Kanou, Hisao Kuboi, Youichi Fukino, Nobutada Kida, Kazutoshi Amano, Sadao |
author_facet | Kawasaki, Atsushi Mimatsu, Kenji Oida, Takatsugu Kanou, Hisao Kuboi, Youichi Fukino, Nobutada Kida, Kazutoshi Amano, Sadao |
author_sort | Kawasaki, Atsushi |
collection | PubMed |
description | A 69-year-old female visited our department with a diagnosis of rectosigmoid cancer and multiple hepatic metastases (stage IV). Abdominal CT revealed multiple metastatic lesions in the bilateral lobes of the liver. The primary lesion was considered to be resectable, and high anterior resection of the rectum was performed. After the operation, 6 courses of therapy with bevacizumab (BV) and modified FOLFOX6 were performed. CT showed a partial response, and tumor marker levels became normal. After a total of 11 courses of this therapy, grade 3 peripheral neuropathy developed, and the therapy was changed to BV and capecitabine (Cape). After 6 courses of this therapy, CT showed the maintenance of partial response, and tumor marker levels were also within the normal range. BV and Cape therapy may be useful not only for reducing peripheral neuropathy, but also as a maintenance therapy in patients requiring the suspension of oxaliplatin administration due to peripheral neuropathy. |
format | Text |
id | pubmed-3037991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-30379912011-02-15 A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer Kawasaki, Atsushi Mimatsu, Kenji Oida, Takatsugu Kanou, Hisao Kuboi, Youichi Fukino, Nobutada Kida, Kazutoshi Amano, Sadao Case Rep Gastroenterol Published: January 2011 A 69-year-old female visited our department with a diagnosis of rectosigmoid cancer and multiple hepatic metastases (stage IV). Abdominal CT revealed multiple metastatic lesions in the bilateral lobes of the liver. The primary lesion was considered to be resectable, and high anterior resection of the rectum was performed. After the operation, 6 courses of therapy with bevacizumab (BV) and modified FOLFOX6 were performed. CT showed a partial response, and tumor marker levels became normal. After a total of 11 courses of this therapy, grade 3 peripheral neuropathy developed, and the therapy was changed to BV and capecitabine (Cape). After 6 courses of this therapy, CT showed the maintenance of partial response, and tumor marker levels were also within the normal range. BV and Cape therapy may be useful not only for reducing peripheral neuropathy, but also as a maintenance therapy in patients requiring the suspension of oxaliplatin administration due to peripheral neuropathy. S. Karger AG 2011-01-14 /pmc/articles/PMC3037991/ /pubmed/21326855 http://dx.doi.org/10.1159/000323138 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published: January 2011 Kawasaki, Atsushi Mimatsu, Kenji Oida, Takatsugu Kanou, Hisao Kuboi, Youichi Fukino, Nobutada Kida, Kazutoshi Amano, Sadao A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer |
title | A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer |
title_full | A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer |
title_fullStr | A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer |
title_full_unstemmed | A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer |
title_short | A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer |
title_sort | case of long partial response to combination therapy of bevacizumab and capecitabine for liver metastases of rectal cancer |
topic | Published: January 2011 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037991/ https://www.ncbi.nlm.nih.gov/pubmed/21326855 http://dx.doi.org/10.1159/000323138 |
work_keys_str_mv | AT kawasakiatsushi acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT mimatsukenji acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT oidatakatsugu acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kanouhisao acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kuboiyouichi acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT fukinonobutada acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kidakazutoshi acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT amanosadao acaseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kawasakiatsushi caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT mimatsukenji caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT oidatakatsugu caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kanouhisao caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kuboiyouichi caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT fukinonobutada caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT kidakazutoshi caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer AT amanosadao caseoflongpartialresponsetocombinationtherapyofbevacizumabandcapecitabineforlivermetastasesofrectalcancer |